Rakuten Medical closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical's ASP-1929 antibody-drug conjugate
SAN MATEO, Calif., July 7, 2020 /PRNewswire/ --Rakuten Medical, Inc. (Rakuten Medical) announced they have entered a multi-year deal with Merck KGaA, Darmstadt, Germany under which Merck KGaA,Darmstadt, Germanywill provide cetuximab to Rakuten Medical for its ASP-1929 program.
- SAN MATEO, Calif., July 7, 2020 /PRNewswire/ --Rakuten Medical, Inc. (Rakuten Medical) announced they have entered a multi-year deal with Merck KGaA, Darmstadt, Germany under which Merck KGaA,Darmstadt, Germanywill provide cetuximab to Rakuten Medical for its ASP-1929 program.
- Under this agreement, Rakuten Medical may use cetuximab to produce ASP-1929 for clinical trials and commercial sales.
- "Rakuten Medical is excited to partner with Merck KGaA,Darmstadt, Germany, a leading science and technology company," said Hiroshi Mikitani, Chairman and CEO of Rakuten Medical.
- "Rakuten Medical is committed to partnering with world class companies such as Merck KGaA,Darmstadt, Germanyin order to carry forward its mission to conquer cancer."